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ARTICLE
AHDC1 missense mutations in Xia-Gibbs syndrome
Michael M. Khayat,1,2,14 Jianhong Hu,1,14 Yunyun Jiang,1,14 He Li,1 Varuna Chander,1,2
Moez Dawood,1,2,3 Adam W. Hansen,1,2 Shoudong Li,1 Jennifer Friedman,4 Laura Cross,5
Emilia K. Bijlsma,6 Claudia A.L. Ruivenkamp,6 Francis H. Sansbury,7 Jeffrey W. Innis,8
Jessica Omark O’Shea,9 Qingchang Meng,1 Jill A. Rosenfeld,2 Kirsty McWalter,10 Michael F. Wangler,2,11
James R. Lupski,1,2,12,13 Jennifer E. Posey,2 David Murdock,1,2 and Richard A. Gibbs1,2,*
Summary
Xia-Gibbs syndrome (XGS; MIM: 615829) is a phenotypically heterogeneous neurodevelopmental disorder (NDD) caused by newly
arising mutations in the AT-Hook DNA-Binding Motif-Containing 1 (AHDC1) gene that are predicted to lead to truncated AHDC1 protein synthesis. More than 270 individuals have been diagnosed with XGS worldwide. Despite the absence of an independent assay for
AHDC1 protein function to corroborate potential functional consequences of rare variant genetic findings, there are also reports of individuals with XGS-like trait manifestations who have de novo missense AHDC1 mutations and who have been provided a molecular
diagnosis of the disorder. To investigate a potential contribution of missense mutations to XGS, we mapped the missense mutations
from 10 such individuals to the AHDC1 conserved protein domain structure and detailed the observed phenotypes. Five newly identified
individuals were ascertained from a local XGS Registry, and an additional five were taken from external reports or databases, including
one publication. Where clinical data were available, individuals with missense mutations all displayed phenotypes consistent with those
observed in individuals with AHDC1 truncating mutations, including delayed motor milestones, intellectual disability (ID), hypotonia,
and speech delay. A subset of the 10 reported missense mutations cluster in two regions of the AHDC1 protein with known conserved
domains, likely representing functional motifs. Variants outside the clustered regions score lower for computational prediction of their
likely damaging effects. Overall, de novo missense variants in AHDC1 are likely diagnostic of XGS when in silico analysis of their position
relative to conserved regions is considered together with disease trait manifestations.

Introduction
De novo stop-gain and frameshift mutations in the gene
encoding the AT-Hook DNA-Binding Motif-Containing
1 (AHDC1) protein that are predicted by conceptual
translation to lead to truncated AHDC1 protein synthesis
are well-established as an underlying cause of Xia-Gibbs
syndrome (XGS; MIM: 615829).1–14 Reported truncating
mutations span most of the length of the protein and
include some sites of recurrent, independently arising
de novo events. AHDC1 likely has a function in the nucleus mediated by its AT-hook binding motifs that
are associated with DNA binding.1,15,16 Following the
identification of the first four XGS cases,12 more than
270 individuals with XGS have been identified
throughout the world by the XGS family support group
and staff at the Baylor College of Medicine (BCM) Human Genome Sequencing Center (HGSC). Eighty-four
of these individuals have provided consent for further
research and detailed phenotype and AHDC1 mutation

information, which is housed in a dedicated and secure
XGS Registry.8
As clinical manifestations of XGS overlap with the multitude of other heterogeneous individually rare NDD traits,
all diagnoses so far have been dependent on molecular
diagnostic testing by DNA sequencing approaches, and
the disease is essentially defined by the molecular diagnostic determination of a pathogenic or likely pathogenic
variant identified in AHDC1.12 In the majority of cases, de
novo, pathogenic AHDC1 mutations were identified via trio
exome sequencing, while plausible variants in other genes
were not identified or were excluded based upon absent genotype-phenotype correlation.4,8,12 In instances where de
novo mutation status could not be determined due to the
lack of trio-based sequencing data or the lack of DNA samples from both biological parents for segregation studies,
the pathogenicity of a truncating AHDC1 variant was
established based on the similarity of the clinical manifestations to other individuals with XGS, coupled with predicted damaging effects of the truncating variants.
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Table 1.

Individuals with an identified de novo or suspected de novo missense mutation in AHDC1

Individual #

Nucleotide change

Protein change

Data type

Source

1

c.139C>T

p.Pro47Ser

exome sequencing

XGS Registry

2

c.1459C>T

p.Arg487Trp

exome sequencing

GeneDx

3

c.1610G>A

p.Gly537Asp

comprehensive NGS panel; microarray

XGS Registry

4

c.1642G>A

p.Gly548Ser

WGS/targeted sequencing

DECIPHER (#287553)

5

c.1646G>A

p.Arg549His

exome sequencing; SNP array

DECIPHER (#370261)

6

c.1819G>A

p.Asp607Asn

exome sequencing

XGS Registry

7

c.2374G>C

p.Gly792Arg

exome sequencing; CGH array

XGS Registry, GeneDx

8

c.4042T>C

p.Ser1348Pro

exome sequencing

DECIPHER (#277992)

c.4370A>G

p.Asp1457Gly

exome sequencing

PMID 30858058

c.4432C>T

p.Pro1478Ser

exome sequencing

XGS Registry

9
10

a

Individuals who joined the XGS Registry also contributed clinical data for this study. The source of data for the other individuals is indicated. Other genetic tests
that were also administered are noted under the data type. NGS, next-generation sequencing; WGS, whole-genome sequencing; CGH, comparative genomic
hybridization.
a
Suspected de novo mutation.

Compared to AHDC1 truncating mutations, it remains
challenging to determine which amino acid changes may
be deleterious for AHDC1 function. This challenge is
further exacerbated by lack of a ‘‘biomarker’’ or laboratory
assay to assess protein function. AHDC1 is well conserved
across most vertebrates, with 94% identity between human and mouse proteins. The gene is overall intolerant
to missense variation, with a positive missense Z score of
2.86 and a missense observed-versus-expected mutation
ratio of 0.75 reported in the Genome Aggregation Database
(gnomAD v.2.1.1).17 There are many known rare and ultrarare AHDC1 variants in the gnomAD population control
cohort, however, including 528 missense variants, of
which 98% (518) have a minor allele frequency (MAF) <
0.001. It is not known how many individuals who harbor
rare variant AHDC1 alleles as reported in gnomAD may
potentially have a mild NDD. Therefore, neither the specific amino acid change nor the allelic frequency of a
missense variant is sufficient to infer pathogenicity.
To date, a total of five putatively pathogenic missense
variants in AHDC1 have been reported in the literature or
in accessible public databases (Table 1). Each report leveraged the observation of de novo occurrence of an AHDC1
mutation and phenotypic similarity of a new clinical case
to the previously reported XGS cases to assert as evidence
supportive of pathogenicity. Three of five were in the DECPIHER database, and one was shared via a genetic testing
provider. Gumus6 described a Turkish individual with a
de novo mutation leading to an Asp-to-Gly change at amino
acid position 1,457 and concluded that this led to craniosynostosis, a new phenotypic feature not previously found
in individuals with XGS. Interestingly, an individual in a
cohort with craniosynostosis was reported with an
AHDC1 de novo frameshift mutation (p.C791fs*57).18
This is a position with identical recurring de novo frameshift mutations in at least five other XGS individuals
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with no reported craniosynostosis,1 and whether this is a
phenotypic expansion of the XGS trait or potentially represents a clinical manifestation due to a dual molecular
diagnosis and multilocus pathogenic variation (MPV) remains a question.19
Three entries in DECIPHER20 indicate de novo mutations
at positions 548, 549, and 1,348 (Gly548Ser, Arg549His,
and Ser1348Pro) that have been ascribed to XGS. One
variant reported by GeneDx indicates a possible XGS diagnosis for an individual with a de novo change at position
487 (Arg487Trp). While the de novo origin of these
missense variants and shared phenotypes between these
individuals and the previously reported XGS clinical spectrum are strongly suggestive of XGS molecular diagnoses,
there is no independent functional testing method to
show the impact of these changes on molecular function
or cellular phenotype to objectively and independently
corroborate the findings by an orthogonal experimental
functional assay. In some cases, it is not clear which criteria
were used to eliminate other possible variants in the
genome as potential factors contributing to disease. Therefore, the assignment of each of these AHDC1 mutations as
the underlying cause of the clinical manifestations of these
individuals may be premature.
In this study, we report an additional five individuals
with missense mutations in AHDC1 who were provided a
molecular and clinical diagnosis of XGS. The genotypic
profiles from these individuals, together with the five
from earlier reports of missense variants in AHDC1, are
analyzed (total distinct missense alleles studied: n ¼ 10).
This allelic series is the largest and only such study of
the AHDC1 locus. Moreover, we report the objective
quantitative analysis of XGS trait manifestations in comparison to well-established pathogenic AHDC1 truncating
variant alleles and to other Mendelizing disorders. Collectively, these analyses provide additional evidence for

Human Genetics and Genomics Advances 2, 100049, October 14, 2021

pathogenicity for some, but not all, of the missense variants in AHDC1 that have been ascribed to XGS.

Subjects and methods
Ethics and consent
Approvals for data use for this study fell into three categories. First,
the five individuals who joined the XGS Registry consented for
participation under approval by the BCM Institutional Review
Board (IRB), protocol number H-39945. Second, data from four individuals were used according to the DECIPHER allowable use
agreement or were from published information.6 Third, one family provided data as approved by protocol IRB #170447 (Genomic
Sequencing in Neurologic Disorders) approved by the University
of California at San Diego IRB and Rady Children’s Hospital
Research Compliance. As a result, the mutation data for all 10 individuals were available. Partial phenotype data were also available
for the five ‘‘external’’ individuals, and detailed clinical data were
available for the five individuals who had consented to participation in this study via the XGS Registry.

Subject recruitment and data security
Affected individuals were initially recruited through social media,
e-mail, physician contact, or by word of mouth. The XGS Registry
was configured in a RedCap environment,21 hosted in a local
Health Insurance Portability and Accountability Act (HIPAA)compliant server. Following initial contact, parents of probands
were queried for participation in the XGS Registry and presented
with initial consent forms. Next, they were invited to fully consent
and to either directly deposit clinical records or to enable their
healthcare provider to share their history. Genetic reports and
clinical reports were then independently reviewed by BCM
HGSC investigators. Additional included individuals (not enrolled
in the XGS Registry) were identified through Genematcher22 and
DECIPHER.20

DNA sequence analysis
The initial molecular diagnoses were by a variety of next-generation DNA sequencing methods (Table 1; Supplemental notes).
Follow-up Sanger dideoxy DNA sequencing was performed whenever patient samples were available.

Subject phenotype assessment
Five individuals from the XGS Registry (Table 1) with available
medical reports were reviewed, and clinically ascertained phenotypes were compared to the previously published XGS spectrum.1,8 Affected individuals with a report of low muscle tone or
hypotonia were indicated under one phenotypic category (‘‘hypotonia’’) summarizing the phenotype. Additional phenotypic features that were not part of the previously reported XGS spectrum
were also noted. Limited phenotype data were available for three
of the five individuals who did not join the XGS Registry, where
caregivers provided information (Table 2).

Computational clustering of phenotypic features
We compared Human Phenotype Ontology (HPO) terms representing the phenotypes of both individuals with XGS due to protein-truncating mutations (n ¼ 34) and the five individuals from
the XGS Registry with missense variants to data from Online
Mendelian Inheritance in Man (OMIM). The HPO descriptions

for OMIM diseases with at least five HPO terms were obtained
from the Jackson Laboratory HPO database.23 XGS individual
phenotypes were converted to HPO terms manually. A word matrix was constructed with OMIM disease or XGS individuals in
rows and HPO terms in the columns (0 ¼ absence; 1 ¼ presence).
The OMIM disease/XGS individual similarities were determined
using cosine similarity algorithm based on the co-occurrences
of HPO terms, normalized by term frequency-inverse document
frequency aggregated from all the OMIM diseases (scikit-learn
package in Python). This procedure resulted in pairwise phenotypic similarities between all the OMIM diseases and individuals
with XGS. Pairwise phenotypic similarity scores ranged from
0 (no match) to 1 (highest possible match) and were plotted
into networks using igraph in R. We also trimmed the OMIM disease node to keep the diseases with at least one neighbor with
similarity score > 0.1 (n ¼ 3,464).

Computational prediction of functional impact
AHDC1 missense variants were analyzed by multiple in silico pathogenicity prediction algorithms. These methods included
Missense Tolerance Ratio (MTR),24 Combined Annotation Dependent Depletion (CADD v.1.6),25 Functional Analysis through Hidden Markov Models (FATHMM-XF),26 and REVEL.27 These scores
were then compared to those calculated for AHDC1 missense variants reported in the Genome Aggregation Database (gnomAD
v.2.1.1) control cohort. All variants in this study were scored using
American College of Medical Genetics and Genomics (ACMG)
criteria utilizing VarSome.28

Results
Mutation profile of putative pathogenic missense
AHDC1 variant alleles
A total of 10 individuals with AHDC1 missense mutations were studied. Five of those individuals were from
external reports, and a further five individuals with
missense variants in AHDC1 were separately enrolled in
the XGS Registry (Table 1), together with their genetic
and clinical details. Based on guidelines from the
ACMG, two of the five missense mutations in the XGS
Registry were initially classified as likely pathogenic
(LP), two were variants of uncertain significance (VUS),
and one was classified as likely benign (LB) (Table S1).
Among them, four of the five missense variant alleles
were confirmed to be de novo mutations based on trio
sequencing. The de novo status for variant p.Pro1478Ser
could not be determined, as paternal data were not available. The details of the mutations in these five individuals in the XGS Registry, together with the details of
five previously reported missense variant alleles, are
shown in Figure 1A and in Table 1. Additional clinical
synopsis details are delineated in the individual case reports in the Supplemental notes.
Clustering of missense variants in AHDC1 domains
The distribution of the 10 studied putatively pathogenic
missense mutations were mapped along the length of the
1,603 amino acid primary sequence of the AHDC1 protein.
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Table 2.

Phenotypes, genotypes, and demographic features of individuals with an AHDC1 missense mutation

Patient ID

1

3

5

6

7

8

9

10

Nucleotide change

c.139C>T

c.1610G>A

c.1646G>A

c.1819G>A

c.2374G>C

c.4042T>C

c. 4370A>G

c.4432C>T

Protein change

p.Pro47Ser

p.Gly537Asp

p.Arg549His

p.Asp607Asn

p.Gly792Arg

p.Ser1348Pro

p.Asp1457Gly

p.Pro1478Ser

Age

14 years

10 years

6 years

23 years

12 years

10 years

2 years

11 years

Sex

M

F

F

M

F

M

F

F

Ethnicity

white

African
American/white

white

white

white

white

NA

Latino/Hispanic

Stature (percentile)

<10th

99th

>90th

43rd

99th

30th

1st

1st

Scoliosis

Y

N

N

N

N

N

NA

N

NA

0

Mutation

Growth

Comprehensive skills and language
M-CHAT score

4

NA

NA

15

4

Y

N

N

Y

N

Y

NA

Y

3

3

2

3

3

0

1

1

Age at first word

11 months

3 years

~2 years

2.5 years

2 years

NA

Age using two
words together

~2 years

~4 years

~12–13 years

not recalled

Age at following
command

2 years

NA

NA

has trouble
following command

Autism diagnosis
Current language

a

NA

2–3 years

NA

NA

not reported

NA

1.5 years

Y

Y

Mobility
Hypotonia diagnosis

Y

N

N

Y

Y

Y

Independent walking

Y

Y

Y

Y

walking with support

Y

Y

Age at independent
walking

~2 years

11 months

15 months

1.5 years

2 years

1 year
(Continued on next page)

Table 2.

Continued

Patient ID

1

3

5

6

7

8

9

10

Sleep apnea

N

Y

N

N

N

N

Using breathing
support

N

Y (CPAP at night)

N

N

N

N

MRI

normal

NA

not done

abnormal

abnormal

abnormal

abnormal

abnormal

EEG

normal

NA

NA

NA

normal

NA

abnormal

normal

Seizure

Y

Y

NA

Y

Y

Y

Y

N

Age at first seizure

3 years

NA

22 years

2–3 years

6 years

3 days

NA

Ataxia

N

N

N

Y

Y

Wearing glasses
or contacts

N

Y

N

N

Y

Visual acuity

20/30

hyperopia,
night blindness

normal

NA

Strabismus

N

N

N

N

N

Y

Y

N

coarse facial
features

long palpebral
fissures, deep-set
eyes, hypertelorism,
macrocephaly, cleft
palate

broad forehead,
thin upper lip

macrocephaly
(likely familial)

upslanted palpebral
fissures, microcephaly,
low-set ears

broad forehead,
wide nasal bridge,
brachycephaly,
microtia, clinodactyly
5th finger, mild
microcephaly

almond-shaped eyes,
thin upper lip,
brachycephaly,
microcephaly,
protuberant ears

upslanting palpebral
fissures, microcephaly

Sleep/airway

Neurology
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Y

Vision

NA

Y
hypermetropia

N
hypermetropia

N
NA

Dysmorphic features
Features

Of the total of 10 individuals, five joined the XGS Registry and provided all available clinical data (individuals 1, 3, 6, 7, and 10). Partial data were available for three of the additional five known individuals (5, 8, 9). M-CHAT,
Modified Checklist for Autism in Toddlers; CPAP, continuous positive airway pressure; MRI, magnetic resonance imaging; EEG, electroencephalogram; M, male; F, female; Y, yes; N, no; NA, not applicable.
Current language: 0, no words; 1, <50 words; 2, no sentence but >50 words; and 3, full sentence >200 words.

a

Figure 1. Recorded AHDC1 missense
cases and protein sequence mutability
(A) A total of 10 individuals with de novo or
suspected de novo missense mutations in
AHDC1 are shown.
(B) The AHDC1 missense mutations are
scored using the missense tolerance ratio
score. A lower score indicates a higher
intolerance to missense mutations based
on sequence conservation of population
controls from gnomAD.

Of note, two apparent clusters were observed, which
included seven of the 10 missense variants. Cluster 1 contained four variants, spanning just 71 amino acid positions
(537–607) within or flanking the region of the highly
conserved AT-hook domain 2 and cluster 2, a conserved
REV3L domain (Domain of Unknown Function 4683
[DUF4683]) (individuals 3–6). Cluster 2 consisted of three
variants that spanned 131 residues near the C terminus
of the protein, within or near a second domain that is
conserved with REV3L (individuals 8–10) (Figure 1). One
of these three variants (individual 9) is the mutation in
the previously published report of the affected individual
of Gumus.6 Individual 10 bore a variant in close proximity,
for which de novo status could not be inferred to provide
supportive evidence due to the absence of paternal DNA.
The two cluster regions are predicted to be intolerant to
missense variation due to purifying selection (Figure 1B;
Figure S1).
Three of the 10 missense variants fell outside the clusters. A variant at amino acid position 487 was within 51
residues of the first cluster, but where it ‘‘sits’’ in threedimensional protein space and secondary and tertiary
protein structure is unknown. The variants within individuals 1 (p.Pro47Ser) and 7 (p.Gly792Arg) did not cluster with other variants and the map to undefined
AHDC1 protein regions, with no homology to other
proteins.
Computational prediction of pathogenicity
Nine of 10 de novo or suspected de novo missense mutations in AHDC1 considered here were predicted as LP us-

6

ing in silico pathogenicity scores
including CADD and FATHMM-XF
(Figure S1), with only the variant in
individual 1 showing lower effect.
However, variants within the two
clusters described above tended
to be within the top 10% of the highest pathogenicity score group. In
contrast, the variants in the three individuals who were located outside
the clusters consistently ranked
lower in the calculated overall pathogenicity scores. Scoring using the
REVEL meta predictor elevated the
missense variants in the first cluster to the top 10%,
compared to gnomAD controls.
Other mutation data
Other data, including variants in genes other than AHDC1,
were considered as potential contributors to the clinical
profiles of the individuals with missense AHDC1 mutations who were in the XGS Registry. Individual 1, with a
de novo AHDC1 p.Pro47Ser variant, also harbored LP de
novo missense variant c.10151A>G (p.Asp3384Gly) in
FAT Atypical Cadherin 3 (FAT3). Although FAT3 has not
been definitively associated with a Mendelian disorder,
recently a FAT3 variant has been implicated as a potential
contributor to autism spectrum disorder (ASD).29 Further,
the AHDC1 de novo missense mutation in individual 1
was classified as LB according to ACMG criteria. This classification was supported by the observation of different alleles at the same amino acid position in two individuals in
the gnomAD database—although those alleles were not
observed in the gnomAD reported ‘‘normal’’ (control)
cohort and may also have had disease association.
Individual 2, with missense variant c.1459C>T
(p.Arg487Trp), was potentially highly informative for this
study, as the mutation occurred at position 487, which
was near the proximal boundary of the cluster of four variants spanning amino acid positions 537–607. Consultation with the individual’s caregivers revealed, however,
that the initial genetic evaluation of the AHDC1 missense
mutation noted mosaicism, although further details
were unavailable. Further, features that were atypical for
XGS were noted (Supplemental notes). Overall, it was
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Table 3.

Additional genetic findings in individuals with AHDC1 de novo missense mutations

Case #

Gene(s)

Nucleotide change

Amino acid change

Zygosity

Inheritance pattern

gnomAD AC/AF

Predicted pathogenicity

1

AHDC1

c.139C>T

p.Pro47Ser

heterozygous

de novo

0/0

likely benign

FAT3

c.10151A>G

p.Asp3384Gly

heterozygous

de novo

0/0

likely pathogenic

SERPINA1

c.863A>G

p.Glu288Val

heterozygous

maternal

0/0

uncertain significance

AHDC1

c.1610G>A

p.Gly537Asp

heterozygous

de novo

0/0

likely pathogenic

ANK3

c.6715C>T

p.Arg2239Cys

heterozygous

paternal

13/0.00005

uncertain significance

APC2

c.4958G>A

p.Arg1653Gln

heterozygous

paternal

58/0.0004

uncertain significance

3

6

7

8a

C5orf42

c.8397A>C

p.Lys2799Asn

heterozygous

maternal

0/0

uncertain significance

SON

c.313A>G

p.Thr105Ala

heterozygous

paternal

9/0.0004

uncertain significance

TTC19

c.380A>G

p.Tyr127Cys

heterozygous

paternal

0/0

uncertain significance

TPM3, C1orf189,
C1orf43, UBAP2L,
HAX1, MIR190B

microdeletion
within 1q21.3

(154,150,447-154,
255,258)x1

heterozygous

unknown

NA

uncertain significance

AHDC1

c.1819G>A

p.Asp607Asn

heterozygous

de novo

0/0

likely pathogenic

DNAH14

c.409C>T

p.Arg137*

heterozygous

paternal

198/0.0007

uncertain significance

DNAH14

c.13548A>T

p.*4516Tyrfs*5

heterozygous

maternal

1,216/0.007

uncertain significance

AHDC1

c.2374G>C

p.Gly792Arg

heterozygous

de novo

0/0

uncertain significance

NPHP1

microdeletion
within 2q13

(110,199,004-110,
337,690)x1

heterozygous

paternal

NA

uncertain significance

ATP11, CXorf661,
MIR505

duplication
within Xq27.1

(138,699,164-139,
089,567)x3

heterozygous

maternal

NA

uncertain significance

AHDC1

c.4042T>C

p.Ser1348Pro

heterozygous

de novo

0/0

likely pathogenic

HUWE1

c.9070G>A

p.Ala3024Thr

hemizygous

de novo

0/0

likely pathogenic

NEB

c.9139C>A

p.His3047Asn

heterozygous

paternal

191/0.0005

benign

NEB

c.7343G>A

p.Arg2448His

heterozygous

maternal

33/0.00008

benign

Data for individuals 1, 3, 6, and 7 were from the XGS Registry. Individual 10, also in the XGS Registry, did not report additional considered variants. AC/AF,
allele count/allele frequency.
a
Data for individual 8, not in the Registry, were provided with consent by the individual’s health provider. Predicted pathogenicity was assessed using VarSome as
described in Subjects and methods.

determined that the p.Arg487Trp change in this individual
is not likely to be contributing to the phenotype, although
it is possible that in other, non-mosaic individuals the
variant may contribute to disease. If the mutation were
not pathogenic, then the remaining four changes in the
cluster region would span just 71 amino acids, including
the critical AT-hook motif.
The diagnosis of individual 8, who harbored a COOHterminal missense variant allele in AHDC1 (p.Ser1348Pro)
was confounded by the presence of a hemizygous LP de
novo missense mutation in the HECT, UBA, and WWE
Domain Containing E3 Ubiquitin Protein Ligase 1
(HUWE1 c.9070G>A [p.Ala3024Thr]) gene. Missense mutations in HUWE1 are highly constrained (missense Z score
¼ 8.87); both SNV and duplication Copy Number Variation involving HUWE1 are known causes of X-linked intellectual disability (ID; MIM: 309590).
No other potentially pathogenic variants were identified in other individuals in this study, although a series
of variants were reviewed and determined to be VUS
(Table 3).

Phenotypic spectrum of individuals with an AHDC1
missense mutation
We previously defined five core and 12 secondary clinically observed phenotypic XGS features, based on the
clinical presentations of 34 individuals with XGS due
to truncating mutations in AHDC1.1 The five core phenotypes were observed in >80% of XGS individuals
and thus perhaps represent a clinical synopsis of the
AD trait associated with this locus. These clinically
observed findings include delayed motor milestones,
ID, hypotonia, low muscle tone, and speech delay,
potentially refining the core AHDC1-associated NDD
trait. For the current study, we combined hypotonia
and low muscle tone into a single category, although
the two features were reported separately during most assessments. We compared the occurrence of these core
and secondary phenotypes derived from individuals
with truncating mutations to those with AHDC1
missense mutations. These comparisons provided evidence that the spectrum of clinical manifestations of individuals reported with putatively pathogenic missense
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Figure 2. Comparison of XGS phenotypes
Data from 34 individuals with XGS due to
truncating AHDC1 mutations were
compared with those from 5 individuals
with suspected or confirmed de novo
missense mutations in AHDC1, who have
joined the XGS Registry.

mutations in AHDC1 largely overlapped with those
harboring truncating mutations (Figure 2).
Of note, all five individuals from the XGS Registry with
missense variants had ID, and four of the five exhibited delayed motor milestones, speech delay, and a diagnosis of
hypotonia/low muscle tone. Individuals in this study
who were ascertained through public databases or previous
studies did not have the same consistent phenotypic
assessment information available as the information content available for those from the XGS Registry. Phenotypes
for subject 2 were not available, and the DECIPHER individuals had limited phenotypic information upon query
(Supplemental notes). However, the majority of cases had
indicated phenotypes of ID and speech delay with the
occurrence of other core phenotypes. An exception to
the phenotypic spectrum associated with the missense mutations, compared to that of the truncating mutations, was
that four of the five individuals in the XGS Registry with
missense mutations reported seizures, compared to an incidence of approximately 50% in the truncation cases. As
this feature is of high clinical relevance, we also examined
the partial phenotype data available from three of the five
external individuals not included in the XGS Registry.
Overall, six of eight XGS individuals reported seizures,
and data for one were not available (Table 2). Notably,
data from individual 10, who had joined the XGS Registry
and indicated ‘‘no’’ for this feature, initially indicated that
the parents had suspected mild seizures. Subsequent physician records, however, indicated a series of normal EEGs
and a record of no seizures. Overall, these data suggest a
higher incidence of seizures in this group of individuals
with missense AHDC1 mutations, relative to truncation
cases. It is not clear if this might represent a gain-of-function (GoF) versus loss-of-function (LoF) mutational effect.
Phenotypic clustering of individuals with missense
mutations
To further investigate phenotypic similarities between individuals with a de novo missense versus a truncation mutation in AHDC1, a comparative analysis utilizing the 17

8

phenotypic terms collected from the
XGS Registry was implemented. The
17 observed clinical phenotype features were converted into HPO terms
and used to compare the phenotypic
similarities among all the individuals
with XGS, as well as the clinical manifestations of 3,464 human disease
traits as defined by the clinical synopsis of individual
entries from OMIM. Data from individuals with missense
variants in AHDC1 clustered together with those from individuals harboring truncating mutations (Figure 3A). In
addition, individuals with a truncation or missense mutation were more similar to each other than to other diseases
with similar phenotypes (Figure 3B). Collectively, by quantitative phenotyping and objective similarity searches, individuals with missense variants were phenotypically
more similar to XGS due to truncating mutations, than
to other disorders.

Discussion
The first 20 individuals reported with an XGS diagnosis
bore de novo protein-truncating mutations, presumably
LoF alleles, leading to speculation that AHDC1 missense
variants may not cause disease.8 Alternative interpretations could be that missense variant alleles might potentially cause GoF versus LoF effects, or perhaps a different
distinct rare disease trait. Truncating AHDC1 mutations
are also predominant among the more than 270 families
with XGS now known worldwide, including 84 who
have joined the XGS Registry. Nevertheless, there are at
least 10 individuals who have been assigned an XGS diagnosis on the basis that they have de novo or suspected de
novo missense mutations in AHDC1. Five of these 10 individuals with missense mutations have joined the XGS Registry and provided detailed clinical phenotyping records
for further study and analyses. One additional family provided limited clinical data, and information from the four
remaining individuals was drawn from DECIPHER or publication. No biomarker or other laboratory assays are yet
available to directly evaluate the biological effect of the
amino acid substitutions on AHDC1 protein function,
and therefore these molecular diagnoses rely considerably
on the de novo status of the changes and the absence of
other variants/loci that parsimoniously explain the
observed clinical features. Further consideration of the genetic and phenotypic data for these reported cases affords
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Figure 3. Phenotypic similarity network
between individuals with AHDC1 variants
and OMIM diseases
(A) Clustering of individuals with an
AHDC1 missense mutation or truncation
mutation with 3,464 diseases reported to
OMIM based on phenotype similarity illustrated by orange dots, blue dots, and green
dots, respectively.
(B) Reclustered OMIM disease nodes with
at least one connection and similarity
>0.1 to individuals with an AHDC1
missense or truncation mutation.

the opportunity to substantiate that missense mutations
can cause XGS. As also suggested by our XGS data analysis
and the FAT3 variation (individual 1), correlation with
clinical phenotyping and expected observations may be
useful in molecular diagnostic interpretation, and the presence of multilocus pathogenic variation needs to be
considered in the molecular differential.30
The amino acid positions of the 10 missense AHDC1
variants reported as underlying XGS suggest a clustering
of events in two primary sequence regions of the protein.
One cluster was striking, as it contained 4/10 mutations
within 71 amino acid residues—less than 5% of the protein. This cluster also contained an AT-hook binding
domain, with two of the missense mutations in the core
AT-hook 12-amino-acid motif.12 The second, more
broadly defined cluster contained three missense variants
and spanned 131 amino acid residues—about 8% of the
protein. The three remaining mutations did not map
to any defined cluster or associate with regions of
strong conservation or computationally defined domains.
Although the structure of AHDC1 is not solved, and 3D
protein effects cannot yet be considered, these data suggest that the variants that arise in either of the two clusters are potentially more likely to perturb normal protein
function.
Algorithmic prediction of the likelihood of the missense
mutations being damaging to the AHDC1 protein also
distinguished variants within the two clusters from the
mutations that occurred in surrounding regions. While
all 10 of the missense AHDC1 variants in this study passed
the likelihood threshold for deleteriousness using the
CADD scores (21.5 to 28.6) to predict their effects, those
outside of the clusters had generally lower scores (21.5 to
24.8). FATHMM-XF analysis further differentiated the
two classes of variants, with all mutations in the clusters reported as LP and the three additional variants with the
lowest scores for pathogenicity (Figure S1C). We also
observed the general trend of most of the clustered mutations being in regions of very low MTR scores, indicating
high intolerance to change (Figure 1B). Overall, the data
and the computational in silico analyses support the gen-

eral model of at least two mutationsensitive regions within the AHDC1
protein.
The information content of quantitative phenotyping
and comparison of phenotypes from individuals with
AHDC1 mutations did not initially provide additional
insight into the true impact of the missense mutations.
The same overall pattern was observed in individuals
with missense mutations versus those with truncating mutations, and when HPO terms were analyzed both groups
had essentially the same distance from other neurological
conditions in OMIM. This was an expected result, as one of
the criteria for the assignment of an XGS diagnosis was
having a similar phenotype to the already-reported individuals. The important question of whether there are individuals who harbor missense AHDC1 alleles with lower
functional impact than any of the missense mutations reported here is unanswered. Such individuals may have
much milder phenotypes and may not present for clinical
evaluation. Hypomorphic alleles may also lead to disease
traits with incomplete penetrance, leading to under-ascertainment of individuals with inherited variant alleles.
Nevertheless, the quantitative analyses of the XGS Registry
data did reveal the association of reported seizures with
these missense cases, and that finding was distinguishable
from what has been reported for truncating alleles. We
speculate that these findings might implicate some potential GoF effects of AHDC1 missense variants.
Together, the data here suggest guidelines for consideration of the possible pathogenicity of newly observed
missense variants in AHDC1 in individuals with XGS-like
phenotypes and in the absence of other genomic variants
that explain an individual’s clinical presentation. Foremost, established guidelines from the ACMG should be
used to guide variant interpretation. These consider most
factors that are contained in the current discussion,
including inheritance pattern and computational predictions of likelihood of damaging effects. The de novo status
of any AHDC1 missense variant should be considered as
a highly important factor for diagnosis, as there is as yet
no evidence for any transmitted variant-causing disease.
Moreover, the position of the mutation might be considered, with variant alleles mapping within either of the
two cluster regions prioritized for assignment as disease
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causing. There are many caveats to these guidelines,
including the imprecision of the knowledge of the cluster
boundaries and the likelihood that with improved understanding of AHDC1 structure and function some missense
changes outside the clusters may be determined to be pathogenic. Nevertheless, it is clear from both the population
data that include many variants in reportedly ‘‘normal’’ individuals and the different presentation of the variant data
from individuals 1, 2, and 7 in this study that pathogenicity cannot be confidently asserted from de novo status
alone. Further, the study underscores the high priority
for both accrual of larger datasets and development of independent functional assays for the protein. One further
potential insight from our missense clinical data regarding
missense constraint and gnomAD-facilitated variant interpretation, and as has also been gleaned from studies of premature truncating codon (PTC) interpretation, there may
be limitations to gnomAD-assisted variant interpretation
when potentially dealing with GoF mutation effects.31–33
The mechanism by which AHDC1 mutations result in
XGS is unknown, and there have been prior suggestions
of both haploinsufficiency and dominant negative effects.1,34 Missense mutations are expected to result in
full-length protein products and are therefore more likely
to act in dominant negative (antimorphic) or other GoF
(neomorphic and hypermorphic) manners. Consequently,
the report here and from prior missense mutations supports the dominant negative model, but it does not
exclude that both haploinsufficiency (LoF) and dominant
negative (GoF) mechanisms could be at play, depending
on the primary mutation.
There are a growing number of early-onset severe neurological Mendelian diseases for which, like XGS, a known
gene with de novo truncating mutations leads to disease.35–37 There is, however, a paucity of well-studied
examples where such loci are also damaged by missense
variants and yield related phenotypes. This is in part likely
due to the complexity of determining causation for
missense variants in disease diagnosis. Where previous
work has identified pathogenic missense variants in genes
that are also associated with autosomal dominant disorders (e.g., NOTCH3), the enrichment of missense variants
in conserved protein domains has been noted.38 This trend
is consistent with observations here of missense mutations
clustering within and near the conserved AT-hook 2
domain and the REV3L homology domain (DUF4683) in
AHDC1.
In summary, we report quantitative phenotyping and
analyses in 10 AHDC1 missense mutations—five novel putative XGS molecular diagnoses and five reported mutations. These novel missense AHDC1 variants newly
described in this study provide confirmatory supportive
evidence that some missense variants in AHDC1 can cause
XGS. Quantitative clinical phenotyping reveals missense
alleles share a core monoallelic NDD autosomal dominant
trait phenotype with that observed in association with LoF
variant alleles but suggests that seizures may more likely be

observed in association with missense alleles. To what
extent such findings might implicate potential GoF effects
remains to be determined by more extensive studies of
AHDC1 allelic series.
Data and code availability
The published article includes all datasets generated or analyzed
during the study. Additional data that support the findings of
this study are available upon request from the corresponding
author, subject to privacy or ethical restrictions. The variants reported here are deposited in the ClinVar database.

Supplemental information
Supplemental information can be found online at https://doi.org/
10.1016/j.xhgg.2021.100049.

Acknowledgments
This work would have not been possible without the contributions
of family members participating in the AHDC1 Xia-Gibbs Registry.
We also thank Drs. Gail E. Herman and Jane Hurst for case referral.
The scientific and experimental work contained herein were
funded in part by the NHGRI awards to R.A.G. (HG008898) and
J.R.L. (NHGRI/NHLBI UM1 HG006542; NINDS R35 NS105078)
and by private donations. V.C. was supported by the training
fellowship from the NLM Training Program in Biomedical
Informatics & Data Science (T15LM007093). H.L. was partially
supported by an award from the Xia-Gibbs Society. J.E.P. was supported by NHGRI K08 HG008986. J.W.I. was supported by the
Morton S. and Henrietta K. Sellner Professorship. This study makes
use of data generated by the DECIPHER community. A full list of
centers who contributed to the generation of the data is available
from DECIPHER and via email from contact@deciphergenomics.
org. Funding for the DECIPHER project was provided by Wellcome. The Deciphering Developmental Disorders (DDD) study
presents independent research commissioned by the Health Innovation Challenge Fund (HICF-1009-003), a parallel funding partnership between Wellcome and the Department of Health, and
the Wellcome Sanger Institute (WT098051). The views expressed
in this publication are those of the author(s) and not necessarily
those of Wellcome or the Department of Health. The study has
UK Research Ethics Committee approval (10/H0305/83, granted
by the Cambridge South REC, and GEN/284/12 granted by the
Republic of Ireland REC). The research team acknowledges the
support of the National Institute for Health Research through
the Comprehensive Clinical Research Network.

Declaration of interests
J.R.L. has stock ownership in 23andMe, is a paid consultant for the
Regeneron Genetics Center, and is a coinventor on multiple US
and European patents related to molecular diagnostics for inherited neuropathies, eye diseases, and bacterial genomic fingerprinting. The Department of Molecular and Human Genetics at
Baylor College of Medicine derives revenue from the chromosomal microarray analysis (CMA) and clinical exome sequencing
(cES) offered in the Baylor Genetics (BG) Laboratory. J.R.L. serves
on the Scientific Advisory Board of BG. J.F.’s spouse is Founder
and Principal of Friedman Bioventure, which holds a variety of

10 Human Genetics and Genomics Advances 2, 100049, October 14, 2021

publicly traded and private biotechnology interests. K.M. is an
employee of GeneDx, Inc. All other authors declare no competing
interests.
Received: May 21, 2021
Accepted: August 4, 2021

Web resources
ClinVar, https://www.ncbi.nlm.nih.gov/clinvar/
DECIPHER, https://www.deciphergenomics.org/about/stats
OMIM, https://omim.org/

References
1. Khayat, M.M., Li, H., Chander, V., Hu, J., Hansen, A.W., Li, S.,
Traynelis, J., Shen, H., Weissenberger, G., Stossi, F., et al.
(2021). Phenotypic and protein localization heterogeneity
associated with AHDC1 pathogenic protein-truncating alleles
in Xia–Gibbs syndrome. Hum. Mutat 42, 577–591.
2. Cardoso-Dos-Santos, A.C., Oliveira Silva, T., Silveira Faccini,
A., Woycinck Kowalski, T., Bertoli-Avella, A., Morales Saute,
J.A., Schuler-Faccini, L., and de Oliveira Poswar, F. (2020).
Novel AHDC1 Gene Mutation in a Brazilian Individual: Implications of Xia-Gibbs Syndrome. Mol. Syndromol. 11, 24–29.
3. Cheng, X., Tang, F., Hu, X., Li, H., Li, M., Fu, Y., Yan, L., Li, Z.,
Gou, P., Su, N., et al. (2019). Two Chinese Xia-Gibbs syndrome
patients with partial growth hormone deficiency. Mol. Genet.
Genomic Med. 7, e00596.
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23. Köhler, S., Gargano, M., Matentzoglu, N., Carmody, L.C.,
Lewis-Smith, D., Vasilevsky, N.A., Danis, D., Balagura, G., Baynam, G., Brower, A.M., et al. (2021). The human phenotype
ontology in 2021. Nucleic Acids Res. 49 (D1), D1207–D1217.

Human Genetics and Genomics Advances 2, 100049, October 14, 2021 11

24. Traynelis, J., Silk, M., Wang, Q., Berkovic, S.F., Liu, L., Ascher,
D.B., Balding, D.J., and Petrovski, S. (2017). Optimizing
genomic medicine in epilepsy through a gene-customized
approach to missense variant interpretation. Genome Res.
27, 1715–1729.
25. Rentzsch, P., Witten, D., Cooper, G.M., Shendure, J., and
Kircher, M. (2019). CADD: predicting the deleteriousness of
variants throughout the human genome. Nucleic Acids Res.
47 (D1), D886–D894.
26. Rogers, M.F., Shihab, H.A., Mort, M., Cooper, D.N., Gaunt,
T.R., and Campbell, C. (2018). FATHMM-XF: accurate prediction of pathogenic point mutations via extended features. Bioinformatics 34, 511–513.
27. Ioannidis, N.M., Rothstein, J.H., Pejaver, V., Middha, S.,
McDonnell, S.K., Baheti, S., Musolf, A., Li, Q., Holzinger, E.,
Karyadi, D., et al. (2016). REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. Am. J.
Hum. Genet. 99, 877–885.
28. Kopanos, C., Tsiolkas, V., Kouris, A., Chapple, C.E., Albarca
Aguilera, M., Meyer, R., and Massouras, A. (2019). VarSome:
the human genomic variant search engine. Bioinformatics
35, 1978–1980.
29. Baldwin, I., Shafer, R.L., Hossain, W.A., Gunewardena, S.,
Veatch, O.J., Mosconi, M.W., and Butler, M.G. (2021).
Genomic, clinical, and behavioral characterization of
15q11.2 bp1-bp2 deletion (burnside-butler) syndrome in five
families. Int. J. Mol. Sci. 22, 1–24.
30. Posey, J.E., Harel, T., Liu, P., Rosenfeld, J.A., James, R.A., Coban
Akdemir, Z.H., Walkiewicz, M., Bi, W., Xiao, R., Ding, Y., et al.
(2017). Resolution of Disease Phenotypes Resulting from Multilocus Genomic Variation. N. Engl. J. Med. 376, 21–31.
31. Poli, M.C., Ebstein, F., Nicholas, S.K., de Guzman, M.M., Forbes, L.R., Chinn, I.K., Mace, E.M., Vogel, T.P., Carisey, A.F., Benavides, F., et al.; Undiagnosed Diseases Network members
(2018). Heterozygous Truncating Variants in POMP Escape
Nonsense-Mediated Decay and Cause a Unique Immune Dysregulatory Syndrome. Am. J. Hum. Genet. 102, 1126–1142.

32. Bayram, Y., White, J.J., Elcioglu, N., Cho, M.T., Zadeh, N., Gedikbasi, A., Palanduz, S., Ozturk, S., Cefle, K., Kasapcopur, O.,
et al.; Baylor-Hopkins Center for Mendelian Genomics (2017).
REST Final-Exon-Truncating Mutations Cause Hereditary
Gingival Fibromatosis. Am. J. Hum. Genet. 101, 149–156.
33. Coban-Akdemir, Z., White, J.J., Song, X., Jhangiani, S.N., Fatih, J.M., Gambin, T., Bayram, Y., Chinn, I.K., Karaca, E., Punetha, J., et al.; Baylor-Hopkins Center for Mendelian Genomics
(2018). Identifying Genes Whose Mutant Transcripts Cause
Dominant Disease Traits by Potential Gain-of-Function Alleles. Am. J. Hum. Genet. 103, 171–187.
34. Quintero-Rivera, F., Xi, Q.J., Keppler-Noreuil, K.M., Lee, J.H.,
Higgins, A.W., Anchan, R.M., Roberts, A.E., Seong, I.S., Fan,
X., Lage, K., et al. (2015). MATR3 disruption in human and
mouse associated with bicuspid aortic valve, aortic coarctation
and patent ductus arteriosus. Hum. Mol. Genet. 24, 2375–
2389.
35. Yang, Y., Muzny, D.M., Reid, J.G., Bainbridge, M.N., Willis, A.,
Ward, P.A., Braxton, A., Beuten, J., Xia, F., Niu, Z., et al. (2013).
Clinical whole-exome sequencing for the diagnosis of mendelian disorders. N. Engl. J. Med. 369, 1502–1511.
36. Bamshad, M.J., Shendure, J.A., Valle, D., Hamosh, A., Lupski,
J.R., Gibbs, R.A., Boerwinkle, E., Lifton, R.P., Gerstein, M., Gunel, M., et al.; Centers for Mendelian Genomics (2012). The
Centers for Mendelian Genomics: a new large-scale initiative
to identify the genes underlying rare Mendelian conditions.
Am. J. Med. Genet. A. 158A, 1523–1525.
37. Posey, J.E., O’Donnell-Luria, A.H., Chong, J.X., Harel, T., Jhangiani, S.N., Coban Akdemir, Z.H., Buysek, S., Pehlivan, D., Carvalho, C.M.B., Baxter, S., et al. (2019). Insights into genetics,
human biology and disease gleaned from family based
genomic studies. Genet. Med 21, 798–812.
38. Turner, T.N., Douville, C., Kim, D., Stenson, P.D., Cooper,
D.N., Chakravarti, A., and Karchin, R. (2015). Proteins linked
to autosomal dominant and autosomal recessive disorders
harbor characteristic rare missense mutation distribution patterns. Hum. Mol. Genet 24, 5995–6002.

12 Human Genetics and Genomics Advances 2, 100049, October 14, 2021

